Intrathecal Enzyme Replacement for Hurler Syndrome

Key facts

Sponsor

Masonic Cancer Center, University of Minnesota

Principal Investigator

Paul Orchard, MD

University of Minnesota Medical Center

Intervention

IRT Laronidase(drug)

Enrollment

26 enrolled

Eligibility

3 years · All sexes

Timeline

2008 – 2018

Study locations (1)

• University of Minnesota, Fairview, Minneapolis, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Hurler syndrome

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE3NCT06149403
  A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT
  Orchard Therapeutics

See all trials for Hurler syndrome →